Advancing quality standards for gene therapies: a USP perspective
Year: 2025
Type: article
Abstract: “Our goal is to ensure that both large and small companies...have access to the analytical tools and reference standards needed for consistent, quality production.” In this interview, Abi Pinchbeck, Editor, BioInsights, speaks to Fouad Atouf, Senior Vice President, Global Biologics, US Pharmacopeia (USP), who provides insights into USP’s evolving role in supporting the cell and gene therapy industry. He discusses USP’s efforts to establish and refine standards to ensure the quality, safety, and efficacy of CGT products, in addition to the future of regulatory convergence in gene therapy development.
Source: Cell and Gene Therapy Insights
Author: Fouad Atouf
Institution: United States Pharmacopeial Convention
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4417327163
FWCI:
Cites:
Cited by:
Related to: